Senolytic therapy in MASH: a potential strategy for reducing fibrosis and preventing hepatocellular carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085838" target="_blank" >RIV/00023001:_____/25:00085838 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Senolytic therapy in MASH: a potential strategy for reducing fibrosis and preventing hepatocellular carcinoma
Original language description
The incidence of metabolic dysfunction-associated steatohepatitis (MASH)increases in patients with metabolic diseases with aging, driven by cumulative metabolic stress,chronic inflammation, and progressive liver fibrosis. Despite extensive research, the limitedefficacy of current therapies, have prompted a search for novel therapeutic options. An example isthe therapeutic influence of cellular senescence, which contributes not only to the development ofmetabolic diseases like MASH, but also to the associated complications. Our goal was thereforeto test the mitochondria-targeted Tamoxifen (MitoTam), a potential anti-cancer agent withsenolytic activity, on reduction of MASH and related pathologies across the age groups.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů